Nermeen Samy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nermeen Samy has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Amany S. El-Bahnasawy
Rheumatology Department, Faculty of Medicine, Mansoura University, Dakahlia, Egypt
4 shared publications - Hanan M. Fathi
Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt
4 shared publications - Maha Emad Ibrahim
Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
4 shared publications - Mervat Ismail Abd Elazeem
Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
4 shared publications - Nevin Hammam
Assuit University
4 shared publications - Rawhya R. El Shereef
Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt
4 shared publications
Latest Publications
- 8 January 2026
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 48 (1) , 95-99
Liver fibrosis assessment in rheumatoid arthritis patients on long-term methotrexate therapy using hepatic fibroScan (transient elastography)
- 8 January 2026
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 48 (1) , 95-99
Liver fibrosis assessment in rheumatoid arthritis patients on long-term methotrexate therapy using hepatic fibroScan (transient elastography)
- Open Access
- 1 December 2025
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 36 (4) , 600-608
Renal Vascular Affection in Systemic Sclerosis Patients and Possible Correlation with Peripheral Vascular Involvement Assessed by Nailfold Capillaroscopy
Background: Symptomatic renal involvement was observed in only 24% of systemic sclerosis (SSc) patients. Objective: We evaluated renal vascular affection, which is linked to disease characteristics and nailfold capillaroscopy (NFC) outcomes in SSc patients Methods: Fifty SSc individuals were subjected to renal doppler ultrasound, NFC, and evaluation of disease severity utilising the Medsger disease severity scale. Results: The cohort comprised 46 females and 4 males, with a mean age of 33.82 ± 11.19 years. Symptomatic renal affection [proteinuria, elevated creatinine level, and mitigated creatinine clearance, and estimated glomerular filtration rate (eGFR) ± hypertension] was observed in 24% of subjects. However, an elevated renal resistive index (RRI) was detected in 44%. Accordingly, patients were allocated into Group 1 (patients exhibiting normal RRI, n = 28) and Group 2 (patients manifesting raised RRI, n = 22). Group 2 patients experienced significantly older age, prolonged disease duration, raised severity scores, protein/creatinine ratio, and avascular NFC scores (p < 0.05). The RRI demonstrated a positive association with age, disease duration, severity, duration of Raynaud's phenomenon, and avascular scores (p < 0.05), alongside negative correlations with creatinine clearance, eGFR, and capillary density (p < 0.05). The main predictors of high RRI encompassed age > 43 years, disease severity score > 5, protein/creatinine ratio > 0.21, capillary density ≤ 6, and avascular score > 1 (p = 0.05). Conclusion: The RRI detected early asymptomatic renal affection, which correlated positively with age, disease duration, severity, and high NFC avascular scores and negatively with creatinine clearance and eGFR. Cite this article as: Samy N, Fayez D, Tantawy SH, Elziaty RA, Abd El-Monem NM, Mohammad Hawwash AM. Renal Vascular Affection in Systemic Sclerosis Patients and Possible Correlation with Peripheral Vascular Involvement Assessed by Nailfold Capillaroscopy. Mediterr J Rheumatol 2025;36(4):600-608. Article Submitted: 29 Apr 2025; Revised Form: 26 May 2025; Article Accepted: 16 Jun 2025; Available Online: 31 Dec 2025 This work is licensed under a Creative Commons Attribution 4.0 International License. ©2025 The Author(s). https://doi.org/10.31138/mjr.290425.vad
- 1 December 2025
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 36 (4) , 600-608
Open AccessRenal Vascular Affection in Systemic Sclerosis Patients and Possible Correlation with Peripheral Vascular Involvement Assessed by Nailfold Capillaroscopy
Background: Symptomatic renal involvement was observed in only 24% of systemic sclerosis (SSc) patients. Objective: We evaluated renal vascular affection, which is linked to disease characteristics and nailfold capillaroscopy (NFC) outcomes in SSc patients Methods: Fifty SSc individuals were subjected to renal doppler ultrasound, NFC, and evaluation of disease severity utilising the Medsger disease severity scale. Results: The cohort comprised 46 females and 4 males, with a mean age of 33.82 ± 11.19 years. Symptomatic renal affection [proteinuria, elevated creatinine level, and mitigated creatinine clearance, and estimated glomerular filtration rate (eGFR) ± hypertension] was observed in 24% of subjects. However, an elevated renal resistive index (RRI) was detected in 44%. Accordingly, patients were allocated into Group 1 (patients exhibiting normal RRI, n = 28) and Group 2 (patients manifesting raised RRI, n = 22). Group 2 patients experienced significantly older age, prolonged disease duration, raised severity scores, protein/creatinine ratio, and avascular NFC scores (p < 0.05). The RRI demonstrated a positive association with age, disease duration, severity, duration of Raynaud's phenomenon, and avascular scores (p < 0.05), alongside negative correlations with creatinine clearance, eGFR, and capillary density (p < 0.05). The main predictors of high RRI encompassed age > 43 years, disease severity score > 5, protein/creatinine ratio > 0.21, capillary density ≤ 6, and avascular score > 1 (p = 0.05). Conclusion: The RRI detected early asymptomatic renal affection, which correlated positively with age, disease duration, severity, and high NFC avascular scores and negatively with creatinine clearance and eGFR. Cite this article as: Samy N, Fayez D, Tantawy SH, Elziaty RA, Abd El-Monem NM, Mohammad Hawwash AM. Renal Vascular Affection in Systemic Sclerosis Patients and Possible Correlation with Peripheral Vascular Involvement Assessed by Nailfold Capillaroscopy. Mediterr J Rheumatol 2025;36(4):600-608. Article Submitted: 29 Apr 2025; Revised Form: 26 May 2025; Article Accepted: 16 Jun 2025; Available Online: 31 Dec 2025 This work is licensed under a Creative Commons Attribution 4.0 International License. ©2025 The Author(s). https://doi.org/10.31138/mjr.290425.vad
- 24 July 2025
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 47 (4) , 207-211
Class V membranous nephropathy in patients with systemic lupus erythematosus: Clinical characteristics, outcome and prognosis
- 24 July 2025
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 47 (4) , 207-211
Class V membranous nephropathy in patients with systemic lupus erythematosus: Clinical characteristics, outcome and prognosis
- 17 January 2025
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 47 (2) , 74-79
Axial involvement in a cohort of patients with psoriatic arthritis
- 17 January 2025
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 47 (2) , 74-79
Axial involvement in a cohort of patients with psoriatic arthritis
- 1 May 2023
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 19 (2) , 180-188
Metabolic Syndrome in Behçets Disease Patients: Keep an Eye on the Eye
Background: Metabolic syndrome (MetS) is characterized by insulin resistance, high blood pres-sure/sugar, dyslipidemia, and obesity. Whether MetS and its components affect the development of Behçet's Disease (BD) remains unclear. Aims: The aim was to determine the frequency of MetS among BD patients and to study its relationship with disease characteristics. Methods: The study included 1028 adult BD patients recruited from 18 specialized rheumatology centers. 51 healthy matched control were considered. Behçet Disease Current Activity Form (BDCAF) and the BD damage index (BDI) were estimated. Adult Treatment Panel-III criteria were used to define MetS. Results: The mean age of patients was 36.8 ± 10.1 years, M:F 2.7:1 and disease duration 7.01 ± 5.2 years. Their mean BDCAF was 5.1 ± 4.6 and BDI 5.5 ± 2.8. MetS was present in 22.8% of patients and in 5.9% of control (3.9 fold higher-risk). Patients with MetS had a significantly increased age at onset (31.8 ± 9.2 vs. 29 ± 8.5 years) and higher frequency of genital ulcers (96.2% vs. 79.7%), skin involvement (73.1% vs. 50.4%), arthritis (48.3% vs. 29.1%) (p<0.0001) and CNS manifestations (18.8% vs. 13%) (p=0.042) compared to those without it. Eye involvement was significantly increased in those with MetS (82.1% vs. 74.2%) (p=0.003) with increased frequency of posterior uveitis (67.1% vs. 43.5%), retinal vessel occlusion (35.9% vs. 21.3%), retinal vasculitis (41.9% vs. 26.4%) (p<0.0001) and vitritis (37.2% vs. 24%) (p=0.001). BDCAF was significantly lower (3.9 ± 4.3 vs. 5.6 ± 4.6) and BDI higher (7.4 ± 2.7vs5 ± 2.6) (p<0.0001). Conclusion: BD patients with MetS are predisposed to mucocutaneous, musculoskeletal, neuropsychiatric and ocular manifestations with consequently increased damage. The involvement of the deeper structures of the eye should alarm rheumatologists to keep in mind that all patients should have an eye examination, especially those with MetS.
- 1 May 2023
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 19 (2) , 180-188
Metabolic Syndrome in Behçets Disease Patients: Keep an Eye on the Eye
Background: Metabolic syndrome (MetS) is characterized by insulin resistance, high blood pres-sure/sugar, dyslipidemia, and obesity. Whether MetS and its components affect the development of Behçet's Disease (BD) remains unclear. Aims: The aim was to determine the frequency of MetS among BD patients and to study its relationship with disease characteristics. Methods: The study included 1028 adult BD patients recruited from 18 specialized rheumatology centers. 51 healthy matched control were considered. Behçet Disease Current Activity Form (BDCAF) and the BD damage index (BDI) were estimated. Adult Treatment Panel-III criteria were used to define MetS. Results: The mean age of patients was 36.8 ± 10.1 years, M:F 2.7:1 and disease duration 7.01 ± 5.2 years. Their mean BDCAF was 5.1 ± 4.6 and BDI 5.5 ± 2.8. MetS was present in 22.8% of patients and in 5.9% of control (3.9 fold higher-risk). Patients with MetS had a significantly increased age at onset (31.8 ± 9.2 vs. 29 ± 8.5 years) and higher frequency of genital ulcers (96.2% vs. 79.7%), skin involvement (73.1% vs. 50.4%), arthritis (48.3% vs. 29.1%) (p<0.0001) and CNS manifestations (18.8% vs. 13%) (p=0.042) compared to those without it. Eye involvement was significantly increased in those with MetS (82.1% vs. 74.2%) (p=0.003) with increased frequency of posterior uveitis (67.1% vs. 43.5%), retinal vessel occlusion (35.9% vs. 21.3%), retinal vasculitis (41.9% vs. 26.4%) (p<0.0001) and vitritis (37.2% vs. 24%) (p=0.001). BDCAF was significantly lower (3.9 ± 4.3 vs. 5.6 ± 4.6) and BDI higher (7.4 ± 2.7vs5 ± 2.6) (p<0.0001). Conclusion: BD patients with MetS are predisposed to mucocutaneous, musculoskeletal, neuropsychiatric and ocular manifestations with consequently increased damage. The involvement of the deeper structures of the eye should alarm rheumatologists to keep in mind that all patients should have an eye examination, especially those with MetS.
- Open Access
- 8 January 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (4) , 667-676
Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.
- 8 January 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (4) , 667-676
Open AccessRheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.
- 16 April 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 989-998
Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
- 16 April 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 989-998
Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
- Open Access
- 9 July 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (9) , 1607-1616
Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
Objectives The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. Methods The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. Results 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). Conclusions The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted.
- 9 July 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (9) , 1607-1616
Open AccessRheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
Objectives The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. Methods The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. Results 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). Conclusions The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted.
- Open Access
- 1 January 2021
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 43 (1) , 29-34
Rheumatoid arthritis patients with interstitial lung disease: Clinical, radiological and laboratory characteristics
- 1 January 2021
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 43 (1) , 29-34
Open AccessRheumatoid arthritis patients with interstitial lung disease: Clinical, radiological and laboratory characteristics
- Open Access
- 1 December 2019
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 31 (4) , 943-950
Vascular endothelial growth factor in systemic lupus erythematosus in correlations with disease activity and nailfold capillaroscopic changes
Background: Angiogenesis plays a role in the pathogenesis of systemic lupus erythematosus (SLE). Both serum vascular endothelial growth factor (VEGF) and capillaroscopic abnormalities may reflect intensity of microcirculatory changes in the course of SLE.Aims: To quantify serum VEGF level and its correlation with microvascular changes, assessed by nailfold capillaroscopy (NFC), and possible relationship with SLE activity.Patients and methods: A total of 90 patients with SLE were subjected to detailed medical history and clinical examination and assessment of disease activity using the SLE Disease Activity Index score and organ damage using Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index. Laboratory investigations were done including autoantibodies [anti-nuclear antibody, anti-DNA, anti-cardiolipin (immunoglobulin G and immunoglobulin M), and lupus anticoagulant]. VEGF serum level was measured using enzyme-linked immunosorbent assay. NFC examination was done for recognition of NFC abnormalities.Results: Serum VEGF level was elevated in the entire study group (mean of 831±572 ng/l), with a statistically highly significant correlation with Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index and SLE Disease Activity Index score of disease activity (r=0.349,P=0.001, andr=0.897,PP=0.002), positive anti-double-stranded DNA (P≤0.001), and consumed C3 and C4 (P≤0.001), which are laboratory markers indicating lupus activity. Moreover, a higher serum VEGF level was associated with severe NFC changes with a statistically highly significant positive correlation with the capillary width (r=0.561,Pr=0.411,Pr=0.308,P=0.003).Conclusion: Increased serum VEGF level and progression of NFC score had been directly related to lupus activity and internal organ involvement, especially nephritis.
- 1 December 2019
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 31 (4) , 943-950
Open AccessVascular endothelial growth factor in systemic lupus erythematosus in correlations with disease activity and nailfold capillaroscopic changes
Background: Angiogenesis plays a role in the pathogenesis of systemic lupus erythematosus (SLE). Both serum vascular endothelial growth factor (VEGF) and capillaroscopic abnormalities may reflect intensity of microcirculatory changes in the course of SLE.Aims: To quantify serum VEGF level and its correlation with microvascular changes, assessed by nailfold capillaroscopy (NFC), and possible relationship with SLE activity.Patients and methods: A total of 90 patients with SLE were subjected to detailed medical history and clinical examination and assessment of disease activity using the SLE Disease Activity Index score and organ damage using Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index. Laboratory investigations were done including autoantibodies [anti-nuclear antibody, anti-DNA, anti-cardiolipin (immunoglobulin G and immunoglobulin M), and lupus anticoagulant]. VEGF serum level was measured using enzyme-linked immunosorbent assay. NFC examination was done for recognition of NFC abnormalities.Results: Serum VEGF level was elevated in the entire study group (mean of 831±572 ng/l), with a statistically highly significant correlation with Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index and SLE Disease Activity Index score of disease activity (r=0.349,P=0.001, andr=0.897,PP=0.002), positive anti-double-stranded DNA (P≤0.001), and consumed C3 and C4 (P≤0.001), which are laboratory markers indicating lupus activity. Moreover, a higher serum VEGF level was associated with severe NFC changes with a statistically highly significant positive correlation with the capillary width (r=0.561,Pr=0.411,Pr=0.308,P=0.003).Conclusion: Increased serum VEGF level and progression of NFC score had been directly related to lupus activity and internal organ involvement, especially nephritis.